ELSEVIER

www.elsevier.nl/locate/jinorgbio

Journal of Inorganic Biochemistry 77 (1999) 265

JOURNAL OF Inorganic Biochemistry

Author Index of Volume 77

Ainscough, E.W., 125
Ali, M.S., 231
Alonso, C., 37, 197
Alvarez-Valdés, A., 37
Appleton, T.G., 13

Babu, P.R., 169
Balcarová, Z., 43
Baran, E.J., 209
Battle, A.R., 3
Beale, P.J., 111
Beggiolin, G., 47
Berners-Price, S.J., 13
Biçer, E., 249
Boccarelli, A., 31
Bolton, A.-M., 13
Brabec, V., 43
Brodie, A.M., 125
Brown, K.L., 185
Brunstrom, G., 95

Çakır, O., 249
Çakır, S., 249
Cardellicchio, N., 31
Carvajal, N., 163
Caserini, C., 59
Castellano, E.E., 209
Cerpa, J., 163
Cervantes, G., 197
Chaney, S.G., 71
Charles, B.G., 13
Colangelo, D., 59
Colbern, G.T., 117
Coluccia, M., 31

Deacon, G.B., 3
Denny, W.A., 125

El-Khateeb, M., 13

Fallon, G.D., 3
Farkas, E., 135
Farrell, N., 43, 47, 51, 59
Finlay, G.J., 125
Fuentes, M., 163
Fujisawa, Y., 215
Fukui, K., 215

Gahan, L.R., 13
Gatehouse, B.M., 3
Gatti, L., 59
Giordano, D., 31
Giraud-Panis, M.-J., 23
González, A.M., 37
González, V.M., 197
Gothe, S.A., 125

Hagopian, G.S., 65
Hambley, T.W., 3
Hanaki, A., 147
Hasinoff, B.B., 257
Henderson, I.C., 117
Henkels, K.M., 83
Hermanson, I.L., 83
Herrera, P., 163
Hiller, A.J., 117
Hiorns, L.R., 95
Howell, S.B., 89
Hu, M.-L., 225

Inoue, H., 239
Intini, F.P., 31

Judson, I.R., 111

Kamada, H., 215
Kanamori, K., 157
Kawashima, T., 147
Kelland, L.R., 95, 111, 121
Keppler, B.K., 141
Khokhar, A.R., 65, 231
Kim, H.-K., 89
Kinoshita, T., 157
Konishi, T., 147
Kozłowski, H., 141

Lawrenz, E.T., 3
Leng, M., 23, 31
Leone, R., 59
Leyland-Jones, B., 95
Lin, X., 89
Lin, S.-J., 205
Locker, D., 31
López, V., 163

Mabuchi, D., 147
Malinge, J.-M., 23
Manzotti, C., 47
Marchal, S., 197
Matsuzawa, H., 205
McGregor, T.D., 43
McKeage, M.J., 105
Michibata, H., 157
Montero, E.I., 37
Moreno, V., 197
Mudasir, 239
Musterer, R.S., 117

Nassi, A., 31
Natile, G., 31
Navarro-Ranninger, C., 37
Newlands, E.S., 95
Nolan, K.B., 135

O'Brien, E.C., 135
O'Neill, C.F., 111
Odani, A., 147
Ohya-Nishiguchi, H., 215

Paradinas, F., 95
Patrick, S.M., 83
Perego, P., 59
Pérez, J.M., 37, 197
Peroutka, J., 47, 51
Piazzoni, L., 47
Piro, O.E., 209
Prieto, M.J., 197

Qu, Y., 43

Rainone, S., 3
Ranford, J.D., 125
Raynaud, F.I., 111
Reddy, K.H., 169
Reddy, P.S., 169
Roberts, J.D., 47, 51
Rockenbauer, A., 135

Sakurai, H., 215
Sakurai, M., 157
Salas, M., 163
Screnci, D., 105
Seckl, M.J., 95
Sharp, S.Y., 95, 111
Shih, M.-K., 225
Siddik, Z.H., 65, 231
Sivo, M., 31
Skelton, L.A., 95
Spinelli, S., 59
Sugden, K.D., 177
Supino, R., 59

Takano, T., 147
Thai, G., 65
Tomisaki, S., 65
Toyomasu, T., 65, 231
Tran, K.T., 257
Tran, M.-C., 43
Trynda-Lemiesz, L., 141
Turchi, J.J., 83

Ueki, T., 157
Uribe, E., 163
Uyama, T., 157

Vaisman, A., 71

Wagner, C.C., 209
Wakagi, T., 205
Webster, L.K., 3
Whitmire, K.H., 231
Working, P.K., 117

Yamauchi, O., 147
Yoshimura, E., 205
Yoshioka, N., 239

Zaludová, R., 43
Zou, X., 185
Zunino, F., 59

Elsevier Science Inc.

ELSEVIER

www.elsevier.nl/locate/jinorgbio

Journal of Inorganic Biochemistry 77 (1999) 267–270

JOURNAL OF Inorganic Biochemistry

Subject Index of Volume 77

Absorption spectra
copper(II)–tripeptide complexes in aqueous solution. Effects of the C-terminal chelate ring size on the coordination structure of doubly deprotonated complex species, 147
Anticancer agents
in vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum–iminoether complexes with different configuration at the iminoether ligands, 31
Antitumor agents
preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [Pt^{II}(1-methylhomopiperazine)(methylmalonato)] · $2H_2O$, 231
Apoptosis
apoptosis induction and inhibition of H-*ras* overexpression by novel *trans*-[$PtCl_2$(isopropylamine)(amine′)] complexes, 37
Aqualysin I
lanthanum binding to aqualysin I, a thermostable serine protease, as probed by lanthanum-139 nuclear magnetic resonance spectrometry, 205
Arginase
manganese-dependent inhibition of human liver arginase by borate, 163

BBR 3464
the cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells, 59
Biopsy samples
a molecular cytogenetic approach to studying platinum resistance, 95
Borate
manganese-dependent inhibition of human liver arginase by borate, 163
Breast cancer
antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model, 117

Cadmium
electrochemical study of cystine in the presence of cadmium and folic acid, 249
Calcium-binding protein
lanthanum binding to aqualysin I, a thermostable serine protease, as probed by lanthanum-139 nuclear magnetic resonance spectrometry, 205
Carboxylates
preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [Pt^{II}(1-methylhomopiperazine)(methylmalonato)] · $2H_2O$, 231
Cell lines
a molecular cytogenetic approach to studying platinum resistance, 95
Cellular accumulation
in vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum–iminoether complexes with different configuration at the iminoether ligands, 31
Cellular pharmacology
cellular pharmacology of polynuclear platinum anti-cancer agents, 51
CGH, testicular germ cell tumours
a molecular cytogenetic approach to studying platinum resistance, 95
Chromium
formation of modified cleavage termini from the reaction of chromium(V) with DNA, 177
Circumvention
mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance, 111
Cisplatin
interstrand cross-links of cisplatin induce striking distortions in DNA, 23
apoptosis induction and inhibition of H-*ras* overexpression by novel *trans*-[$PtCl_2$(isopropylamine)(amine′)] complexes, 37
cellular pharmacology of polynuclear platinum anti-cancer agents, 51
role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance, 65
specificity of platinum–DNA adduct repair, 71
the role of DNA mismatch repair in cisplatin mutagenicity, 89
antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model, 117
Cisplatin/polynuclear platinum complexes
comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines, 47
Cisplatin-damaged DNA
interactions of mammalian proteins with cisplatin-damaged DNA, 83
Cisplatin hydrolytes
reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques, 13
Cisplatin resistance
the cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells, 59
Coenzyme B_{12}
thermolysis of coenzymes B_{12} at physiological temperatures: activation parameters for cobalt–carbon bond homolysis and a quantitative analysis of the perturbation of the homolysis equilibrium by the ribonucleoside triphosphate reductase from *Lactobacillus leichmannii*, 185
Copper(II)–tripeptide complexes
copper(II)–tripeptide complexes in aqueous solution. Effects of the C-terminal chelate ring size on the coordination structure of doubly deprotonated complex species, 147
Copper(II) complexes
synthesis, spectral studies and nuclease activity of mixed ligand copper(II) complexes of heteroaromatic semicarbazones/thiosemicarbazones and pyridine, 169
Crystal structure
a new potentially useful complex for lithium therapies: dimeric monoaqua lithium isoorotate, 209

preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [Pt^{II}(1-methylhomopiperazine)(methylmalonato)] · $2H_2O$, 231
Cysteine
reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques, 13
Cystine
electrochemical study of cystine in the presence of cadmium and folic acid, 249
Cytotoxicity
cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure–activity relationships, 125

Damage-recognition proteins
specificity of platinum–DNA adduct repair, 71
DBP
effect of *cis*-, *trans*-diamminedichloroplatinum(II) and DBP on human serum albumin, 141
cis-DDP
effect of *cis*-, *trans*-diamminedichloroplatinum(II) and DBP on human serum albumin, 141
trans-DDP
effect of *cis*-, *trans*-diamminedichloroplatinum(II) and DBP on human serum albumin, 141
Dexrazoxane
the displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane, 257
Diabetes
in vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy, 215
Dipeptides
metal complexes of taurine. The first reported solution equilibrium studies for complex formation by taurine at physiological pH: the copper(II)–glycylglycinate–taurine and the copper(II)–glycylaspartate–taurine systems, 135
DNA
sequence-dependent conformational changes in DNA induced by polynuclear platinum complexes, 43
interactions of mammalian proteins with cisplatin-damaged DNA, 83
DNA distortion
interstrand cross-links of cisplatin induce striking distortions in DNA, 23
DNA cleavage
formation of modified cleavage termini from the reaction of chromium(V) with DNA, 177
DNA damage
formation of modified cleavage termini from the reaction of chromium(V) with DNA, 177
DNA interaction
DNA binding of iron(II) mixed-ligand complexes containing 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline, 239
DNA mismatch repair
the role of DNA mismatch repair in cisplatin mutagenicity, 89
DNA–Pt–mercaptopyridine interaction
DNA interaction and antitumor activity of a Pt(III) derivative of 2-mercaptopyridine, 197
Drug resistance
role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance, 65

EDTA
direct reduction from vanadium(V) to vanadium(IV) by NADPH in the presence of EDTA. A consideration of the reduction and accumulation of vanadium in the ascidian blood cells, 157
Electrochemistry
electrochemical study of cystine in the presence of cadmium and folic acid, 249
ESEEM
in vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy, 215
ESR spectra
copper(II)–tripeptide complexes in aqueous solution. Effects of the C-terminal chelate ring size on the coordination structure of doubly deprotonated complex species, 147
Excision repair-defective Drosophila
in vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum–iminoether complexes with different configuration at the iminoether ligands, 31

Fluorescence quenching
effect of *cis*-, *trans*-diamminedichloroplatinum(II) and DBP on human serum albumin, 141
Folic acid
electrochemical study of cystine in the presence of cadmium and folic acid, 249
Fused chelate rings
copper(II)–tripeptide complexes in aqueous solution. Effects of the C-terminal chelate ring size on the coordination structure of doubly deprotonated complex species, 147

H-*ras* oncogene
apoptosis induction and inhibition of H-*ras* overexpression by novel *trans*-[$PtCl_2$(isopropylamine)(amine′)] complexes, 37
HER2
antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model, 117
Herceptin®
antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model, 117
Heteroaromatic semicarbazones/thiosemicarbazones
synthesis, spectral studies and nuclease activity of mixed ligand copper(II) complexes of heteroaromatic semicarbazones/thiosemicarbazones and pyridine, 169
Homopiperazine
preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [Pt^{II}(1-methylhomopiperazine)(methylmalonato)] · $2H_2O$, 231
Human liver
manganese-dependent inhibition of human liver arginase by borate, 163
Human serum albumin
effect of *cis*-, *trans*-diamminedichloroplatinum(II) and DBP on human serum albumin, 141

Inductively coupled plasma atomic emission spectroscopy
effect of *cis*-, *trans*-diamminedichloroplatinum(II) and DBP on human serum albumin, 141
Insulin
in vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy, 215
Interfacial interactions
electrochemical study of cystine in the presence of cadmium and folic acid, 249

Interstrand cross-links
interstrand cross-links of cisplatin induce striking distortions in DNA, 23
Iron
the displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane, 257
Iron(II)
DNA binding of iron(II) mixed-ligand complexes containing 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline, 239

JM216
specificity of platinum–DNA adduct repair, 71

Kinetics
the displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane, 257

^{139}La NMR spectroscopy
lanthanum binding to aqualysin I, a thermostable serine protease, as probed by lanthanum-139 nuclear magnetic resonance spectrometry, 205
Lipid peroxidation
relative roles of metal ions and singlet oxygen in UVA-induced liposomal lipid peroxidation, 225
Liposomes
relative roles of metal ions and singlet oxygen in UVA-induced liposomal lipid peroxidation, 225
Lithium isoorotate
a new potentially useful complex for lithium therapies: dimeric monoaqua lithium isoorotate, 209
Lithium therapies
a new potentially useful complex for lithium therapies: dimeric monoaqua lithium isoorotate, 209
Losoxantrone
the displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane, 257

Mammalian proteins
interactions of mammalian proteins with cisplatin-damaged DNA, 83
Manganese
manganese-dependent inhibition of human liver arginase by borate, 163
2-Mercaptopyridine
DNA interaction and antitumor activity of a Pt(III) derivative of 2-mercaptopyridine, 197
Metal ions
relative roles of metal ions and singlet oxygen in UVA-induced liposomal lipid peroxidation, 225
Methionine
reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques, 13
Microsatellite instability
the role of DNA mismatch repair in cisplatin mutagenicity, 89
Mixed-ligand complex
DNA binding of iron(II) mixed-ligand complexes containing 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline, 239
Molecular cytogenetics
a molecular cytogenetic approach to studying platinum resistance, 95
Mutagenicity
the role of DNA mismatch repair in cisplatin mutagenicity, 89

NADPH
direct reduction from vanadium(V) to vanadium(IV) by NADPH in the presence of EDTA. A consideration of the reduction and accumulation of vanadium in the ascidian blood cells, 157
Neuroprotective approaches
platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches, 105
Nuclease activity
synthesis, spectral studies and nuclease activity of mixed ligand copper(II) complexes of heteroaromatic semicarbazones/thiosemicarbazones and pyridine, 169
Nucleotide excision repair
specificity of platinum–DNA adduct repair, 71

Oxaliplatin
specificity of platinum–DNA adduct repair, 71
Oxovanadium(IV) complex
in vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy, 215
Oxygen radicals
formation of modified cleavage termini from the reaction of chromium(V) with DNA, 177

p53
role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance, 65
Partial inhibition
manganese-dependent inhibition of human liver arginase by borate, 163
Pegylated liposomal cisplatin
antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model, 117
1,10-Phenanthroline
DNA binding of iron(II) mixed-ligand complexes containing 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline, 239
Piroxantrone
the displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane, 257
Plasma ultrafiltrate
reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques, 13
Platinum
preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of $[Pt^{II}(1\text{-methylhomopiperazine})(methylmalonato)]\cdot 2H_2O$, 231
Platinum drugs
mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance, 111
Platinum(IV) complexes
modifying the properties of platinum(IV) complexes in order to increase biological effectiveness, 3
trans-Platinum–iminoether
in vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum–iminoether complexes with different configuration at the iminoether ligands, 31
Platinum neurotoxicity
platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches, 105
Platinum resistance
a molecular cytogenetic approach to studying platinum resistance, 95
Polynuclear platinum
cellular pharmacology of polynuclear platinum anti-cancer agents, 51

Polynuclear platinum complexes
sequence-dependent conformational changes in DNA induced by polynuclear platinum complexes, 43
Post-replication repair
specificity of platinum–DNA adduct repair, 71
Pt–mercaptopyridine complex
DNA interaction and antitumor activity of a Pt(III) derivative of 2-mercaptopyridine, 197
Pt(III) complex antitumor activity
DNA interaction and antitumor activity of a Pt(III) derivative of 2-mercaptopyridine, 197
Pulsed EPR
in vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy, 215

Reduction
direct reduction from vanadium(V) to vanadium(IV) by NADPH in the presence of EDTA. A consideration of the reduction and accumulation of vanadium in the ascidian blood cells, 157
Resistance
mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance, 111
Ribonucleoside triphosphate reductase
thermolysis of coenzymes B_{12} at physiological temperatures: activation parameters for cobalt–carbon bond homolysis and a quantitative analysis of the perturbation of the homolysis equilibrium by the ribonucleoside triphosphate reductase from *Lactobacillus leichmannii*, 185

Salicylaldehyde benzoylhydrazone
cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure–activity relationships, 125
Serine protease
lanthanum binding to aqualysin I, a thermostable serine protease, as probed by lanthanum-139 nuclear magnetic resonance spectrometry, 205
Singlet oxygen
relative roles of metal ions and singlet oxygen in UVA-induced liposomal lipid peroxidation, 225
Spectroscopic studies
a new potentially useful complex for lithium therapies: dimeric monoaqua lithium isoorotate, 209
SPI-077
antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model, 117
Stability constants
metal complexes of taurine. The first reported solution equilibrium studies for complex formation by taurine at physiological pH: the copper(II)–glycylglycinate–taurine and the copper(II)–glycylaspartate–taurine systems, 135
copper(II)–tripeptide complexes in aqueous solution. Effects of the C-terminal chelate ring size on the coordination structure of doubly deprotonated complex species, 147
Structure–activity relationships
cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure–activity relationships, 125
Structures in solution
copper(II)–tripeptide complexes in aqueous solution. Effects of the C-terminal chelate ring size on the coordination structure of doubly deprotonated complex species, 147
Synthesis
preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of $[Pt^{II}(1\text{-methylhomopiperazine})(methylmalonato)]\cdot 2H_2O$, 231

Taurine
metal complexes of taurine. The first reported solution equilibrium studies for complex formation by taurine at physiological pH: the copper(II)–glycylglycinate–taurine and the copper(II)–glycylaspartate–taurine systems, 135
Ternary copper complexes
metal complexes of taurine. The first reported solution equilibrium studies for complex formation by taurine at physiological pH: the copper(II)–glycylglycinate–taurine and the copper(II)–glycylaspartate–taurine systems, 135
Thermodynamic parameters
DNA binding of iron(II) mixed-ligand complexes containing 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline, 239
Thermolysis
thermolysis of coenzymes B_{12} at physiological temperatures: activation parameters for cobalt–carbon bond homolysis and a quantitative analysis of the perturbation of the homolysis equilibrium by the ribonucleoside triphosphate reductase from *Lactobacillus leichmannii*, 185
Thermostability
lanthanum binding to aqualysin I, a thermostable serine protease, as probed by lanthanum-139 nuclear magnetic resonance spectrometry, 205
Toxicity
role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance, 65
Tunicates
direct reduction from vanadium(V) to vanadium(IV) by NADPH in the presence of EDTA. A consideration of the reduction and accumulation of vanadium in the ascidian blood cells, 157

UVA
relative roles of metal ions and singlet oxygen in UVA-induced liposomal lipid peroxidation, 225

Vanadium
direct reduction from vanadium(V) to vanadium(IV) by NADPH in the presence of EDTA. A consideration of the reduction and accumulation of vanadium in the ascidian blood cells, 157